Miguel A. Villalona

Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.

Eric K. Rowinsky, Lee Smith, Y M Wang et al. · Journal of Clinical Oncology · 1998 · 146 citations

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

Amita Patnaik, Eric K. Rowinsky, Miguel A. Villalona et al. · PubMed · 2002 · 124 citations

Chemoprevention Strategy, Pathology, Pharmacotherapy +16

A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863

Alan P. Venook, Colin Klein, Gini F. Fleming et al. · Annals of Oncology · 2003 · 81 citations · Full text

Urology, Radiation Medicine, Hepatology +9

Creating Diverse Target-Binding Surfaces on FKBP12: Synthesis and Evaluation of a Rapamycin Analogue Library

Xiànghóng Wú, Lisheng Wang, Yaohua Han et al. · ACS Combinatorial Science · 2011 · 35 citations

Altered<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi mathvariant="bold">p</mml:mi><mml:mn mathvariant="bold">1</mml:mn><mml:msup><mml:mrow><mml:mn mathvariant="bold">6</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="bold">I</mml:mi><mml:mi mathvariant="bold">N</mml:mi><mml:mi mathvariant="bold">K</mml:mi><mml:mn mathvariant="bold">4</mml:mn></mml:mrow></mml:msup></mml:math>and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer

Weiqiang Zhao, Cheng Huang, Gregory A. Otterson et al. · Journal of Oncology · 2012 · 29 citations · Full text